A phase IIa, open-label, multi-centre study of TP300 as a single agent first line therapy in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.

Trial Profile

A phase IIa, open-label, multi-centre study of TP300 as a single agent first line therapy in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs TP 300 (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Aug 2014 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
    • 20 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by UKCRN.
    • 25 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top